Cognitive performance is associated with worse prognosis in patients with heart failure with reduced ejection fraction

Patrícia Fino^{1,2,3}, Rita Matos Sousa^{1,2,3}, Renata Carvalho^{1,2,3}, Nuno Sousa^{1,2,3}, Filipa Almeida⁴ and Vítor Hugo Pereira^{1,2,3,5*}

¹Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal; ²ICVS/3B's, PT Government Associate Laboratory, Braga/ Guimarães, Portugal; ³Clinical Academic Center, Braga, Portugal; ⁴Cardiology Department, Hospital Senhora da Oliveira, Guimarães, Portugal; ⁵Hospital Santa Maria Maior, Barcelos, Portugal

Abstract

Aims Heart failure (HF) is a complex clinical syndrome with multiple comorbidities. Cognitive impairment, stress, anxiety, depression, and lower quality of life are prevalent in HF. Herein, we explore the interplay between these parameters and study their value to predict major adverse cardiovascular events (MACEs) and health-related quality of life (HrQoL) in patients with HF with reduced ejection fraction using guideline recommended assessment tools.

Methods and results We conducted a longitudinal study using a sample of 65 patients from two hospitals. A battery of tests was applied to assess cognition [Montreal Cognitive Assessment (MoCA)], stress (Perceived Stress Scale-10), anxiety, and depression (Hospital Anxiety and Depression Scale) at baseline. MACEs were registered using clinical records. HrQoL was estimated using the Kansas City Cardiomyopathy Questionnaire (KCCQ). A descriptive statistical analysis was conducted, and multiple linear and Cox regression models conducted to determine the predictive value of neurocognitive parameters and HrQoL in MACE. Both MoCA [hazard ratio = 0.906 (0.829–0.990); P = 0.029] and KCCQ scores were predictors of MACE, but not of overall mortality. Anxiety, depression, and stress scores did not predict MACE. However, anxiety ($\beta = -0.326$; P = 0.012) and depression levels ($\beta = -0.309$; P = 0.014) were independent predictors of the KCCQ score.

Conclusions The MoCA score and HrQoL were predictors of MACE-free survival. Anxiety and depression were good predictors of HrQoL, but not of MACE-free survival.

Keywords Cognitive impairment; Heart failure; Quality of life; Major adverse cardiovascular events; Montreal Cognitive Assessment (MoCA)

Received: 29 January 2020; Revised: 13 July 2020; Accepted: 19 July 2020

*Correspondence to: Vitor Hugo Pereira, Life and Health Sciences Research Institute (ICVS), Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal. Tel: +35 125 3604923. Email: vitorpereira@med.uminho.pt

Patrícia Fino and Rita Matos Sousa contributed equally to this work

Institutions where work was performed: Cardiology Department, Hospital Senhora da Oliveira, Guimarães, Portugal; Hospital Santa Maria Maior, Barcelos, Portugal; Clinical Academic Center, Braga.

Introduction

Patients with heart failure (HF) have a worst health-related quality of life (HrQoL) when compared with healthy populations and patients with other chronic diseases.¹ HF has a multisystemic impact, including mental health. Several studies show that HF is associated with a high prevalence of neuropsychological disorders such as depression,² anxiety,³ psychological stress,⁴ and cognitive impairment (CI).⁵

Evidence suggests that some of these factors are associated with prognosis. For example, patients with a higher prevalence of depressive symptoms are at higher risk of mortality and poorer HF outcomes.^{6,7} Recently, the OPERA-HF study investigated the prognostic value of psychosocial factors in HF and showed that moderate-to-severe depression, anxiety, and CI increase the risk of repeated admissions.⁸ Despite the importance of these findings, the sample was composed of both patients with reduced and preserved ejection

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

fraction, which adds heterogeneity to the analysis. Besides, the tool used to assess cognitive performance on this trial was not amongst the ones suggested by the European Society of Cardiology.⁹ In fact, using different tools to assess cognitive performance and the heterogeneity of the populations studied may justify the wide range of CI prevalence reported in HF (25% to 80% across studies).^{5,10–12} The European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic HF suggest the screening of CI using specific instruments such as the Montreal Cognitive Assessment (MoCA) or the Mini-Mental State Examination.⁹ While these two tools were validated in clinical studies, MoCA identifies clinical relevant CI more often than Mini-Mental State Examination.^{13,14} However, no previous study has followed HF with reduced ejection fraction (HFrEF) patients over time using guideline-recommended tools to assess both CI and HrQoL.

In this context, the current report aims to further explore the interplay between neuropsychological parameters, HrQoL, and prognosis in a sample of ambulatory patients with HFrEF.

Methods

We performed a longitudinal observational study using a convenience sample composed of 65 outpatients with HFrEF under follow-up in the cardiology department of two hospitals in the North of Portugal (Guimarães and Barcelos).

The inclusion criteria were (i) HF patients under follow-up in an outpatient clinic, (ii) clinically stable and under maximum tolerated medical treatment without medication changes in the last 6 months, and (iii) left ventricular ejection fraction <40% in transthoracic echocardiogram (Simpson biplane method). The exclusion criteria were (i) hospitalization for HF decompensation in the previous 6 months, (ii) history of clinical stroke, and (iii) CI due to neuropsychiatric diseases or individuals unable to complete the questionnaires (severe visual or auditory deficits).

The participants were submitted to a battery of four scales/questionnaires to assess depressive and anxiety symptoms, cognitive function, perceived stress, and quality of life. Herein, we analyse the health outcomes of these patients during a 2 year follow-up (July 2016 to June 2018).

The battery of scales/questionnaires was composed by MoCA,^{15,16} for cognitive performance evaluation; Kansas City Cardiomyopathy Questionnaire (KCCQ)^{17,18} for quality of life, Perceived Stress Scale-10^{19,20} to assess psychological stress and the Hospital Anxiety and Depression Scale (HADS)^{21,22} to assess anxiety and depression. Previously, validated Portuguese versions of each questionnaire were used.

MoCA is a cognitive screening instrument with greater sensitivity than the Mini-Mental State Examination to detect neurocognitive deficits, namely, mild Cl.¹⁴ It assesses different cognitive domains: attention, concentration, executive functions, memory, language, visual-constructional skills, conceptual thinking, calculations, and orientation; its maximum score is 30 points. We use the cut-off for mild Cl according to the MoCA Portuguese version, as validated and normalized by Freitas and colleagues.^{16,23}

Regarding the HADS-A and HADS-D scales, we used the following cut-offs: normal if value <8, abnormal if >10, and borderline if 8–10.²¹ For Perceived Stress Scale-10, values above 19 indicate high levels of perceived stress.²⁰

A clinical interview was also performed to assess the New York Heart Association (NYHA) class and overall symptoms. Clinical data were retrieved from the clinical records of the patients.

For the follow-up, the primary endpoint was major adverse cardiovascular event (MACE)-free survival time. MACE was defined as the composite of cardiovascular (CV) hospitalizations, CV emergency department admissions, and CV deaths. A more comprehensive characterization was also performed including the total number of hospitalizations, the total number of emergency department visits, and the current clinical status based on the clinical record of the last outpatient clinic visit. During the follow-up period, medical treatment changes were allowed according to the clinical judgement of the assistant cardiologists. A systematic recording of medical compliance was not performed.

All participants signed the informed consent and the study received approval from the Ethics Committees of both hospitals. The Declaration of Helsinki,²⁴ the Council of Europe's Convention on Human Rights,²⁵ and Biomedicine and the Council for International Organizations of Medical Science's guidelines²⁶ were strictly followed.

Results

Baseline evaluation

The cohort was composed of 83% male participants, with an average age of 63 years old and 5.6 years of school (*Table* 1). The aetiology of HF was ischemic disease in 63% of the patients (52% had a previous myocardial infarction). About 62% were in NYHA class II at the beginning of the follow-up. Anxiety had been previously diagnosed in 17% of patients and depression in 9%. On the cognitive evaluation, 92% of the patients were classified as having mild Cl. The scores in anxiety and depressive scales reached the clinical cut-off of abnormal in 45% and 48% of the patients. Thirty-seven per cent of patients presented a 'high level of perceived stress'.

One of the objectives of this work was to understand how the neuropsychological parameters are related to each other. These results are displayed in *Table 2*. Given the importance

 Table 1 Characterization of the cohort: medical background and heart failure

Cander (male) 54 (83.10%) Age (yars) W = 6.292 (SD = 3.35) Wone 1 (1.5%) 1-2 0 (0.0%) 3-4 41 (63.1%) 5-32 41 (20.0%) 5-34 1 (20.0%) 5-44 1 (62.1%) 1-3 4 (2.%) 1-4 1 (20.0%) 1-3 4 (2.%) 1-4 1 (20.0%) 1-3 4 (2.%) 1-4 1 (20.0%) 1-5 4 (4.6%) 1-6 50 = 0.081) Weight (10, 1) 1.4 (2.6%) Medical background 29 (44.6%) Dabdets mellitus 29 (44.6%) Hypertension 27 (41.5%) Dabdets mellitus 29 (44.6%) Hypertension 31 (50.7%) Dabdets mellitus 29 (44.6%) Hypertension 31 (50.7%) Dabdets mellitus 29 (44.6%) Hypertension 31 (50.7%) Dabdets mellitus 29 (44.6%) Hypertension 31 (6.0%)	Characteristic	N (%)
Years of school M = 5.57 (SD = 3.35) Nome 1 (1.5%) 1-2 0 (0.0%) 1-3 (16.3.1%) 5-4 1 (20.0%) 5-4 (16.3.1%) 5-4 (16.3.1%) 5-4 (16.3.1%) 5-4 (16.3.1%) 5-4 (16.3.1%) 1-3 (16.3.1%) 1-3 (16.3.1%) Shoing Status (16.3.1%) Alcohol consumption (29.2.3%) Physical activity M = 15.6 (SD = 0.081) Height (Kg) M = 7.2 (R = 16) SMI (Kg/m ²) 26.43 (SD = 5.2.2) Merical background M = 9.85 (SD = 12.4) Merical background M = 9.85 (SD = 12.4) Merical background (15.3.1%) Merical background (24.6.1%) Opplipidization 3 (6.7%) Mycardial infaction 3 (5.7%) Opplipidizets (16.3.1%) Attail finillation 3 (6.7%) Opplipidizets (16.2.3.1%) Opplipidizets <t< td=""><td></td><td></td></t<>		
None 1 (1.5%) 3-4 1 (1.5%) 3-4 4 (63.1%) 3-4 4 (63.1%) 3-4 4 (63.1%) 3-4 4 (63.1%) 3-4 4 (63.1%) 3-12 6 (2.2%) 13+ 4 (2.8%) 13-4 3 (2.0%) Action consumption 2 (2.2.8%) Physical activity 19 (29.2.3%) Medical background 2 (4.4.9%) More 1 - 166 (SD = 0.081) Weight (kg) More 1 - 166 (SD = 0.081) Weight (kg) More 1 - 166 (SD = 0.081) Medical background Medical background 2 (4.4.9%) Medical background 2 (4.4.9%) Medical background 2 (4.4.9%) Debelse mellitus 2 (4.4.9%) Debelse mellitus 2 (4.4.9%) Debelse mellitus 2 (4.4.9%) Debelse mellitus 2 (4.4.9%) Depelsion 2 (4.4.9%) CoPON (optimilitation) 3 (6.0.7%) Myroid disease (6.1.9%) COPON (optimil		
1-2 0 (0.0%) 3-4 4 (63.1%) 5-8 13 (20.0%) 13 (40.0%) (63.1%) 13 (40.0%) (63.1%) 13 (40.0%) (63.1%) 13 (40.0%) (63.1%) Mathing tatus (62.%) Actobil consumption 29(23.8%) Physical activity M = 16.6 (5D = 0.081) Height (fm) M = 126.3 (5D = 5.22) Normal veight 27 (41.5%) Adominal perimeter (cm) M = 98.63 (5D = 12.4) Mule (kg/m ³) 26.43 (3D = 5.22) Normal veight 27 (45.5%) Adominal perimeter (cm) M = 98.63 (5D = 12.4) Mycacatal infaction 33 (5D,7%) Phypertension 54 (63.1%) Mycacatal infaction 33 (5D,7%) Mycacatal infaction 33 (5D,7%) Mycacatal infaction 34 (65%) Chepros-Stokes 4 (62.7%) Heart failure astology (schemic) 13 (16.5%) Throid disasse 12 (18.9%) Mittarre astology (schemic) 14 (63.7%) <td< td=""><td></td><td></td></td<>		
3-4 41 (63.1%) 9-12 6 (9.2%) 13+ 6 (9.2%) Disking status 9 (13.8%) Probing status 9 (13.8%) Probing status 9 (13.8%) Physical activity 10 (29.2%) Heightin 10 (29.2%) Mode status 20 (13.8%) Physical activity 10 (29.2%) Mode status 20 (13.5%) Adominal permeter (cm) Mode = 7.2 (R = 16) Medical background 27 (41.5%) Adominal permeter (cm) 49 88.35 (SD = 12.4) Medical background 29 (44.6%) Hypertension 21 (44.6%) Advisit Minihalon 31 (80.7%) Moradial infarction 31 (80.7%) Moradial infarction 31 (80.7%) Moradial infarction 31 (45.3%) CoPD/Disthma 10 (16.9%) Thyoid disease (6 (2.2%) CoPD/Disthma 11 (16.6%) Unit 41 (63.1%) Unit 41 (63.2%) CoPD/Disthma 12 (18.5%) Im 41 (63.2%) CoPD/Disthma 12 (18.5%) Im 41 (63.2%) CoPD/Disthma 12 (18.5%) Im 41 (63.2%) CoPD-		
9-12 6 (9.2%) 13+ 4 (6.2%) Living alore 3 (4.6%) Stocking status 9 (13.8%) Alcohol consumption 29(23.8%) Physical activity 29(23.8%) Height (kg) M = 1.66 (SD = 0.081) Weight (kg) 26.43 (SD = 5.22) BM (kg/m ²) 26.43 (SD = 5.22) Medical background M = 98.85 (SD = 12.4) Medical background M = 98.85 (SD = 12.4) Medical background 32 (65.9%) Obabetes mellitus 29 (44.6%) Myportanial infarction 33 (50.7%) Myportanial infarction 33 (46.6%) Atrial fibrillation 33 (46.6%) Myporatial infarction 34 (52.3%) Depression 6 (9.2%) Anxiety 11 (16.9%) Thyroid disease 6 (9.2%) COPD/sathma 12 (18.50%) III 10 (5.40%) VTHA functional class 12 (18.50%) III 40 (61.50%) VTHA functional class 12 (18.50%) III	3–4	
13+ 4 (6.2%) Lining alome 3 (4.6%) Smoking status 9 (13.8%) Ackohol consumption 29 (23.8%) Physical activity 19 (29.2%) Mingum? 29 (24.3%) Weight (kg) Man = 72 (1R = 16) BMI (kg/m?) 26 43 (50 = 5.21) Normal weight 27 (41.5%) Adominal perimeter (cm) 29 (44.6%) Medical background 29 (44.6%) Medical background 39 (55.2%) Medical background 39 (56.2%) Advisit filteriation 33 (52.3%) Oppersion 6 (92.7%) Advisit filteriation 33 (50.7%) Mycoardial infarction 34 (63.0%) Oppersion 6 (92.7%) Advisit filteriation 34 (63.0%) Oppersion 6 (92.7%) COPDyasthma 10 (15.9%) I 11 (16.3%) Oppersion 4 (62.7%) Oppersion 4 (62.7%) CoPDyasthma 12 (18.5%) I 10 (16.30%) I 11 (16.30%) I 12 (18.5%) II 13 (20.00%) II 13 (20.00%) II 13 (20.00%) II 13 (20.00%)		
Living alone 3 (4.6%) Stroking status 9 (13.8%) Atcohol consumption 29(23.8%) Height (m) M = 1.66 (SD = 0.081) Weight (kg) 26.43 (SD = 5.22) Normal veight 29 (43.6%) Normal veight 29 (44.6%) Addomial perimeter (m) 29 (44.6%) Diable sergured 29 (44.6%) Diable sergured 29 (44.6%) Mycardial infaction 33 (50.7%) Atrial fibrillation 33 (50.7%) Mycardial infaction 34 (52.3%) Depression 6 (9.2%) Amiety 11 (16.9%) Thyroid disease 6 (9.2%) COPD/satha 3 (4.6%) Normal veight 11 (16.9%) Thyroid disease 6 (9.2%) Copene-Stokes 4 (6.2%) Height (n) 14 (63.0%) With functional class 12 (18.5%) III 11 (16.9%) More 12 (18.5%) 14 (63.0%) With functional class 12 (18.5%) III 16 (24.6%)		
Smoking status 9 (13.8%) Acchol consumption 29(23.8%) Physical activity 19 (29.2%) Mil (kg/m ²) Mdn = 72 (R = 16) Weight (kg) Mdn = 72 (R = 16) Addominal perimeter (cm) 26 43 (50 = 5.22) Normal weight 27 (41.5%) Addominal perimeter (cm) 9 (84.6%) Metical background 29 (44.6%) Diabets members 29 (44.6%) Mypertension 37 (55.9%) Advand fibrillation 34 (53.9%) Oppression 6 (9.2%) Advand fibrillation 34 (53.9%) Advand fibrillation 11 (16.9%) Thyroid disease 6 (9.2%) COPOyashma 12 (2.1%) Sleep disorders 1 Umed disease (> 1 year) 13 (20.0%) I 40 (61.50%) I 1 14 (63.0%)		
Alcoho Consumption 29(23.8%) Physical activity 19 (22.2%) Height (kg) M = 1.65 (SD = 0.081) Weight (kg) XM = 1.65 (SD = 0.081) SMI (kg/m²) 26.43 (SD = 5.22) Normal weight 27 (41.5%) Abdominal perimeter (cm) M = 98.85 (SD = 12.4) Medical background 29 (44.6%) Physical activity 29 (44.6%) Physical activity 31 (SD.7%) Atrial fibrillation 34 (52.3%) Optimizer 6 (9.2%) Atrial fibrillation 34 (52.3%) Optimizer 6 (9.2%) Atrial fibrillation 34 (52.3%) Optimizer 6 (9.2%) Atrial fibrillation 5 (23.1%) Mycoardial infarction 34 (52.3%) Optimizer 11 (16.9%) Mycoardial infarction 34 (52.3%) Optimizer 4 (6.7%) Cheyme-Stokes 4 (6.2%) Cheyme-Stokes 4 (6.2%) Cheyme-Stokes 4 (6.2%) II 12 (18.50%) III		
Height (m) M = 1.65 (SD = 0.081) Weight (kg) M = 1.61 BMI (kg/m ²) 26.43 (SD = 5.22) Normal weight 27 (41.5%) Abdominal perimeter (cm) M = 98.85 (SD = 12.4) Medical background 29 (44.6%) Phypertension 27 (64.5%) Dysipidaemia 54 (83.1%) Atrial fibrillation 34 (52.3%) Depression 6 (9.2%) Arrial fibrillation 34 (52.3%) Objective (Kg/m) 11 (16.9%) Thyroid disease 6 (9.2%) CCPD/Dashtma 10 CDepression 3 (46.7%) Copene-Stokes 3 (46.7%) Chenge-Stokes 3 (46.7%) Time of disease (>1 year) 13 (20.00%) Time of disease (>1 year) 13 (20.00%) III 14 (50.6 (SD = 7.6) 35-40% 16 (24.6%) <35% ⁷² 49 (75.4%) <t< td=""><td></td><td></td></t<>		
Weight (kg) Md (kg/m) 26.43 (SD = 5.22) Normal weight 27 (41.5%) Abdominal perimeter (cm) M = 98.85 (SD = 12.4) Medical background 29 (44.6%) Hypertension 37 (55.9%) Diabetes mellitus 29 (44.6%) Hypertension 34 (52.3%) Dyslipidaemia 54 (83.1%) Atrial fibrillation 33 (50.7%) More and infarction 34 (52.3%) Depression 6 (9.2%) Anxiety 11 (16.9%) Thryoid disease 6 (9.2%) COPD/osthma 15 (22.1%) See gloorders 3 (4.6%) CSA 3 (4.6%) Cherne-Stokes 4 (6.2%) Heart failure actiology (ischemic) 11 (16.30%) Time of disease (>1 year) 58 (89.4%) Pro-BNP (pg/mL) 13 (20.00%) Hunctional class 10 (15.40%) II 12 (18.50%) II 12 (18.50%) III 13 (20.00%) IVP of disease (>1 year) 14 (61.50%) III </td <td></td> <td></td>		
BMI (kg/m ²) 26.43 (SD = 5.22) Normal weight 27 (41.5%) Abdominal perimeter (m) M = 98.85 (SD = 12.4) Biabetes mellitus 29 (44.6%) Pubpettes mellitus 29 (44.6%) Pypettension 37 (55.9%) Dysipidaemia 54 (83.1%) Arrial fibrillation 33 (50.7%) Myocardial infarction 34 (52.3%) Depression 6 (9.2%) Anxiety 11 (16.9%) Thyroid disease 6 (9.2%) COPD/pathma 15 (23.1%) Steep disorders 34 (46.6%) Cheyne-Stokes 4 (6.5.9%) Ime of disease (>1 year) 58 (89.4%) NTHA functional class 1 I 12 (18.50%) II 13 (20.09%) IN 13 (20.09%) IVEF M = 234 (IR = 359.3) Rythm (strial fibrillation) 10 (15.40%) Left bundle branch block 48 (73.80%) Tastboracic exhocardiogram 10 (15.40%) LVEF M = 24.5 (SD = 7.6) 35-40%		
Normal weight 27 (41.5%) Addominal preimeter (cm) # 98.85 (SD = 12.4) Medical background 9 (44.6%) Hypertension 27 (65.9%) Myperation infraction 33 (50.7%) Myocardial infraction 33 (50.7%) Myocardial infraction 34 (52.3%) Depression 6 (9.2%) Anxiety 11 (16.9%) Thyroid disease 6 (9.2%) COPP(Jasthma 15 (23.1%) Sleep disorders 3 (4.6%) COPP(Jasthma 15 (23.1%) Sleep disorders 4 (6.30%) OSA 3 (4.6%) Cheyme-Stokes 4 (6.30%) Heart failure acilogy (ischemic) 11 (16.30%) Time of disease (>1 year) 58 (89.4%) VPHA functional class 1 II 40 (61.50%) III 40 (61.50%) III 40 (61.50%) III 40 (75.40%) III 40 (75.40%) III 40 (61.50%) III 40 (75.40%) III <td></td> <td></td>		
Abdominal perimeter (m) M = 98.85 (SD = 12.4) Piabetes mellitus 29 (44.6%) Diabetes mellitus 29 (44.6%) Pyspertension 37 (55.9%) Dysipidaemia 54 (83.1%) Atrial fibrillation 33 (50.7%) Myocardial infarction 34 (52.3%) Depression 6 (9.2%) Anxity 11 (16.3%) Thyroid disease 6 (9.2%) COPD/sathma 15 (23.1%) Steep disorders (6.2%) Cheyne-Stokes 4 (6.3%) Heart failure aetiology (ischemic) 41 (63.0%) Time of disease (c-1 year) S8 (89.4%) NVHA functional class 1 I 12 (18.50%) II 13 (20.00%) IN 13 (20.00%) IVEF M = 28.6 (SD = 7.6) Stado% 73.8%) Transthoracic exhocardiogram I////////////////////////////////////		
Diabetes mellitus 29 (44.6%) Hypertension 37 (56.9%) Dysipidaemia 54 (83.1%) Arrial fibrillation 34 (52.3%) Myocardial infarction 34 (52.3%) Depression 6 (9.2%) Anxiety 11 (16.9%) Thyroid disease 6 (9.2%) COPD/asthma 5 (23.1%) Step disorders 15 (23.1%) Cheyne-Stokes 4 (6.2%) Cheyne-Stokes 4 (6.2%) Cheyne-Stokes 4 (6.3.0%) Time of disease (>1 year) 58 (89.4%) NPIA functional class 12 (18.50%) I 13 (20.00%) II 40 (61.50%) II 40 (61.50%) II 40 (61.50%) III		
Hypertension 37 (56 9%) Dyslipidemia 54 (83 1%) Arial fibrillation 33 (50 7%) Myocardial infarction 34 (52.3%) Depression 6 (9.2%) Arixity 11 (16.9%) Thyroid disease 6 (9.2%) COPP/bathma 15 (23.1%) Step disorders 3 (4.6%) Cheyne-Stokes 4 (6.2%) Heart failure actiology (ischemic) 41 (63.0%) Imme of disease (>1 year) 58 (89.4%) NYHA functional class 1 I 10 (61.50%) II 14 (63.0%) II 14 (61.20%) II 14 (61.0%) III 14 (61.0%) III 12 (18.50%) III 14 (61.0%) III 14 (61.0%) III 14 (61.0%) III 14 (61.0%) III 12 (18.50%) III 14 (63.0%) IIII 12 (18.50%) IIII 12 (18.50%) IIIIIIIIIIIIIIIIIIIIIIIIIII		
Djsipidaemia 54 (83.1%) Aria fibrilizion 33 (50.7%) Mycardial infarction 34 (52.3%) Depression 6 (9.2%) Anxiety 11 (16.9%) Thyroid disease 6 (9.2%) COPD/asthma 15 (23.1%) Step disorders 3 Chenne-Stokes 4 (63.0%) Chenne-Stokes 4 (63.0%) Heart failure actiology (ischemic) 41 (63.0%) Time of disease (>1 year) 58 (89.4%) VHA functional class 1 I 13 (20.00%) II 40 (61.50%) III 50 (50 =		
Afrait Ibrillation 33 (50,7%) Myocardial infarction 34 (52,3%) Depression 6 (9,2%) Anxiety 11 (16,9%) Thyroid disease 6 (9,2%) COPD/Jasthma 15 (23,1%) Siege disorders 3 OSA 3 (4,6%) Cheyne-Stokes 4 (62,2%) Heart failure actiology (schemic) 41 (63,0%) Time of disease (>1 year) 58 (89,4%) NYHA functional class 1 I 13 (20,00%) II 40 (61,50%) II 40 (61,50%) III 5 (20,00%) III	51	
Mycardial infarction 34 (52.3%) Depression 6 (9.2%) Anxiety 11 (16.9%) Thyroid disease 6 (9.2%) COPD/asthma 15 (23.1%) Sleep disorders 3 (4.6%) Cheyne-Stokes 4 (62.9%) Heart failure arcilogy (ischemic) 31 (63.0%) Time of disease (>1 year) 58 (89.4%) NYHA functional class 1 I 12 (18.50%) III 13 (20.0%) Pro-SNP (pg/mL) M = 1294 (IR = 3593) Rhythm (atrial fibrillation) 10 (15.40%) Left bundle branch block 48 (73.80%) Tarasthoracic echocardiogram 49 (75.4%) LVEF M = 28.6 (SD = 7.6) 35-40% 49 (75.4%) < 35%^5		
Anxiety 11 (16.9%) Thyroid disease 6 (9.2%) COPD/asthma 15 (23.1%) Sleep disorders 3 (4.6%) Cheyne-Stokes 4 (6.2%) Time of disease (>1 year) 58 (99.4%) WHA functional class 1 I 12 (18.50%) III 13 (20.00%) Pro-BNP (pg/mL) M = 1294 (IR = 3593) Rhythm (atrial fibrillation) 10 (15.40%) Left bundle branch block 40 (61.50%) Tarasthoracic echocardiogram m = 28.6 (SD = 7.6) Z54.40% 49 (75.4%) 49 (75.4%) LA diameter M = 45.4 (SD = 6.2) E/A ratio M = 45.4 (SD = 7.8) LV end diastolic volume M e6.97 (SD = 25.6) Morate/ regurgitation m = 137 (IR = 64) Moderate/severe 10 (15.40%) No/Mid <td>Myocardial infarction</td> <td></td>	Myocardial infarction	
Thyroid disease $6 (9.2\%)$ COPD/asthma $15 (23.1\%)$ Sleep disorders $3 (4.6\%)$ OSA $3 (4.6\%)$ Cheyne-Stokes $4 (5.2\%)$ Heart failure actiology (ischemic) $4 (5.2\%)$ Time of disease (> 1 year) $58 (89.4\%)$ NYHA functional class 1 I $40 (61.50\%)$ II $40 (61.50\%)$ III $40 (61.50\%)$ IIII $40 (61.50\%)$ IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII		
COPUpasthma 15 (23.1%) Sleep disorders 3 (4.6%) Cheyne-Stokes 4 (62%) Heart failure actiology (ischemic) 41 (63.0%) Time of disease (>1 year) 58 (89.4%) NYHA functional class 1 I 12 (18.50%) III 13 (20.00%) Pro-BNP (pg/mL) M (61.50%) NPth functional class 48 (73.80%) Transthoracic echocardiogram 49 (75.4%) LVF M = 42.6 (SD = 7.6) 35-40% 16 (24.6%) <35% ^{70%} 49 (75.4%) LVF M = 43.4 (SD = 6.2) EAF ratio M = 43.4 (SD = 6.2) LV end diastolic diameter M = 62.4 (SD = 7.8) LV end diastolic diameter M = 62.4 (SD = 7.8) LV end diastolic diameter M = 63.4 (SD = 7.8) No/Mid S (80.0%) Moderate/severe 10 (15.40%) No/Mid moderate/severe 5 (80.0%) No/decrate 5 (80.0%) Moderate 5 (80.0%) Right ventricular dysfunction 4 (70.8%) <td></td> <td></td>		
Sheep disorders 3 (4.6%)OSA3 (4.6%)Cheyne-Stokes4 (6.2%)Heart failure actiology (ischemic)41 (63.0%)Time of disease (>1 year)48 (89.4%)NYHA functional class1112 (18.50%)II40 (61.50%)III40 (61.50%)III13 (20.00%)Pro-BNP (pg/mL)M = 1294 (R = 3593)Rhythm (atrial fibrillation)10 (15.40%)Left bundle branch block48 (73.80%)Transthoracic echocardiogramM = 28.6 (SD = 7.6)235-40%16 (24.6%)<35-40%		
OSA 3 (4.6%) Cheyne-Stokes 4 (6.2%) Heart failure actiology (ischemic) 41 (63.0%) Time of disease (-1 year) 58 (89.4%) NYHA functional class 1 I 18.50%) II 40 (61.50%) III 40 (61.50%) III 40 (61.50%) III 10 (15.40%) III 10 (15.40%) III 10 (15.40%) III 120.00%) Pro-BNP (pg/mL) M = 1294 (IR = 3593) Rhythm (atrial fibrillation) 10 (15.40%) Left bundle branch block 48 Transthoracic echocardiogram W LVEF M = 28.6 (SD = 7.6) 35-40% 16 (24.6%) <35% ^{7/5} 49 (75.4%) LA diameter M = 62.4 (SD = 6.2) LF ratio M = 64.1 (SD = 6.9) K/A ratio M = 62.7 (SD = 7.6) UV end diastolic diameter M = 62.4 (SD = 7.8) LV end diastolic volume M = 61.4 (SD = 7.8) Mitral regurgitation M = 62.4 (SD = 7.		15 (25.170)
Heart failure actiology (ischemic) 41 (63.0%) Time of disease (>1 year) 58 (89.4%) I 12 (18.50%) I 40 (61.50%) II 40 (61.50%) III 13 (20.00%) Pro-BNP (pg/mL) M = 1294 (IR = 3593) Rhythm (arial fibrillation) 10 (15.40%) Left bundle branch block 48 (73.80%) Transthoracic echocardiogram 49 (75.4%) LVEF M = 45.4 (SD = 6.2) 35-40% 49 (75.4%) LA diameter M = 45.4 (SD = 6.9) E/A ratio M = 69.7 (SD = 25.6) LV end diastolic diameter M = 62.4 (SD = 7.8) LV end diastolic volume Md = 137 (IR = 64) Mitral regurgitation 10 (15.40%) Noderate/severe 10 (15.40%) Noderate 58 (20%) Ri		3 (4.6%)
Time of disease (>1 year) 58 (89.4%) NYHA functional class 1 I 12 (18.50%) II 13 (20.00%) Pro-BNP (pg/mL) M = 1294 (IR = 3593) Rhythm (atrial fibrillation) 10 (15.40%) Left bundle branch block 48 (73.80%) Transtoracic echocardiogram $W = 28.6 (SD = 7.6)$ JS5-40% 16 (24.6%) <35%/^2		
NYHA functional class1I12 (18.50%)II40 (61.50%)III13 (20.00%)Pro-BNP (pg/mL)M = 1294 (IR = 3593)Rhythm (atrial fibrillation)10 (15.40%)Left bundle branch block48 (73.80%)Transthoracic echocardiogram10 (15.40%)LVEFM = 28.6 (SD = 7.6) $35-40\%$ 16 (24.6%) $<35\%^{1/2}$ 49 (75.4%)L diameterM = 45.4 (SD = 6.2)EV ratioM = 45.4 (SD = 6.2)EV ratioM = 69.7 (SD = 25.6)LV end diastolic diameterM de 137 (IR = 64)No/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation10 (15.40%)No56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy60 (92.3%)Adotserone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Nitrates5 (77%)Digoxin18 (27.7%)Nitrates5 (77%)Digoxin17 (26.2%)Acetyfaaling/lic acid36 (55.4%)		
112 (18.50%)II40 (61.50%)III13 (20.00%)Pro-BNP (pg/mL)M = 1294 (IR = 3593)Rhythm (atrial fibrillation)10 (15.40%)Left bundle branch block48 (73.80%)Transtoracic echocardiogram $48 (73.80%)$ LVEFM = 28.6 (SD = 7.6)35-40%16 (24.6%)<35%/2		58 (89.4%)
II 40 (61.50%) III 13 (20.00%) Pro-BNP (pg/mL) M = 1294 (IR = 3593) Rhythm (atrial fibrillation) 10 (15.40%) Left bundle branch block 48 (73.80%) Transthoracic echocardiogram M = 28.6 (SD = 7.6) Transthoracic echocardiogram M = 28.6 (SD = 7.6) LVEF M = 28.6 (SD = 6.2) <35-40%		12 (18 50%)
Pro-BNP (pg/mL) $M = 1294$ ($R = 3593$)Rhythm (atrial fibrillation)10 (15,40%)Rhythm (atrial fibrillation)10 (15,40%)Left bundle branch block48 (73.80%)Transthoracic echocardiogram $M = 28.6$ (SD = 7.6) $LVEF$ $M = 28.6$ (SD = 7.6) $35-40\%$ 16 (24.6%) $< 35\%^{7/2}$ 49 (75.4%)LA diameter $M = 45.4$ (SD = 6.2)E/C ratio $M = 45.4$ (SD = 6.2)E/Z ratio $M = 69.7$ (SD = 25.6)LV end diastolic diameter $M = 69.7$ (SD = 25.6)LV end diastolic volume $M = 69.7$ (SD = 25.6)LV end diastolic volume $M = 69.7$ (SD = 6.4)Mitral regurgitation $S1$ (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation56 (91.8%)Moderate56 (20.8%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy40 (70.8%)ACEI or ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivabradine7 (10.8%)Other pharmacologic therapy17 (26.2%)Martarin72 (26.2%)		
Rhythm (atrial fibrillation)10 (15.40%)Left bundle branch block48 (73.80%)Transthoracic echocardiogram W LVEFM = 28.6 (SD = 7.6)35-40%16 (24.6%)<35% ⁷⁵ 49 (75.4%)LA diameterM = 45.4 (SD = 6.2)E/E ratioM = 14.1 (SD = 6.9)E/A ratioM = 69.7 (SD = 25.6)LV end diastolic diameterM = 62.4 (SD = 7.8)LV end diastolic volumeM dm = 137 (IR = 64)Mitral regurgitationTricuspid regurgitationNo/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation56 (91.8%)Moderate5 (82.0%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy53 (81.5%)Liver of ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivadradine7 (10.8%)Other pharmacologic therapy17 (26.2%)Warfarin17 (26.2%)Acetylsalicylic acid36 (55.4%)		13 (20.00%)
Left bundle branch block48 (73.80%)Transtoracic echocardiogram VEF JS-40%M = 28.6 (SD = 7.6)35-40%16 (24.6%)<35% ^{7/>} 49 (75.4%)LA diameterM = 45.4 (SD = 6.2)E/E ratioM = 14.1 (SD = 6.9)E/A ratioM = 69.7 (SD = 25.6)LV end diastolic diameterM = 62.4 (SD = 7.8)LV end diastolic volumeMdn = 137 (IR = 64)Mitral regurgitationMNo/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy65 (100%)Actel or ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivabradine7 (10.8%)Other pharmacologic therapy7 (26.2%)Warfarin17 (26.2%)Acetylsalicylic acid36 (55.4%)		
Transthoracic echocardiogramLVEFM = 28.6 (SD = 7.6) $35-40\%$ 16 (24.6%) $<35\%^{7/2}$ 49 (75.4%)LA diameterM = 45.4 (SD = 6.2)E/E ' ratioM = 14.1 (SD = 6.9)E/A ratioM = 69.7 (SD = 25.6)LV end diastolic diameterM = 62.4 (SD = 7.8)LV end diastolic volumeMdn = 137 (IR = 64)Mitral regurgitationTricuspid regurgitationNo/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy7 (10.8%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivabradine7 (10.8%)Other pharmacologic therapy7 (10.8%)Warfarin17 (26.2%)Acetylsalicylic acid36 (55.4%)		
LVEFM = 28.6 (SD = 7.6) $35-40\%$ 16 (24.6%) $<35\%^{7/2}$ 49 (75.4%)LA diameterM = 45.4 (SD = 6.2)E/E' ratioM = 69.7 (SD = 25.6)LV end diastolic diameterM = 69.7 (SD = 7.8)LV end diastolic volumeM = 62.4 (SD = 7.8)LV end diastolic volumeMdn = 137 (IR = 64)Mitral regurgitation51 (84.60%)No/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation56 (91.8%)No56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy65 (100%)ACEI or ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivabradine7 (10.8%)Other pharmacologic therapy7Warfarin17 (26.2%)Acetylsalicylic acid36 (55.4%)		46 (75.80 %)
$<35\%^{7/>}$ 49 (75.4%)LA diameterM = 45.4 (SD = 6.2)E/F ratioM = 14.1 (SD = 6.9)E/A ratioM = 69.7 (SD = 25.6)LV end diastolic diameterM = 62.4 (SD = 7.8)LV end diastolic volumeMdn = 137 (IR = 64)Mitral regurgitation10 (15.40%)No/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation56 (91.8%)No56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy65 (100%)ACEI or ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivabradine7 (10.8%)Other pharmacologic therapy17 (26.2%)Acetylsalicylic acid36 (55.4%)	5	M = 28.6 (SD = 7.6)
LA diameter $M = 45.4$ (SD = 6.2)E/E' ratio $M = 14.1$ (SD = 6.9)E/A ratio $M = 69.7$ (SD = 25.6)LV end diastolic diameter $M = 62.4$ (SD = 7.8)LV end diastolic volumeMdn = 137 (IR = 64)Mitral regurgitation $Ti (84.60\%)$ No/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation $56 (91.8\%)$ No56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy $65 (100\%)$ ACEI or ARA $60 (92.3\%)$ Beta-adrenergic blockers $60 (92.3\%)$ Aldosterone antagonists $53 (81.5\%)$ Diuretics $46 (70.8\%)$ Nitrates $5 (77\%)$ Digoxin $18 (27.7\%)$ Ivabradine $7 (10.8\%)$ Other pharmacologic therapy $7 (10.8\%)$		16 (24.6%)
E/E' ratioM = 14.1 (SD = 6.9) E/A ratioM = 69.7 (SD = 25.6) LV end diastolic volumeM = 62.4 (SD = 7.8) LV end diastolic volumeMdn = 137 (IR = 64)Mitral regurgitation51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy65 (100%)ACEI or ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics5 (77%)Digoxin18 (27.7%)Nitrates5 (77%)Vabradine7 (10.8%)Other pharmacologic therapy17 (26.2%)Acetylsalicylic acid36 (55.4%)		
E/A ratioM = 69.7 (SD = 25.6)LV end diastolic diameterM = 62.4 (SD = 7.8)LV end diastolic volumeMdn = 137 (IR = 64)Mitral regurgitation51 (84.60%)No/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation5 (82.0%)No56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy65 (100%)ACEI or ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Nabradine7 (10.8%)Other pharmacologic therapy77 (26.2%)Acetylsalicylic acid36 (55.4%)		
LV end diastolic diameterM = 62.4 (SD = 7.8)LV end diastolic volumeMdn = 137 (IR = 64)Mitral regurgitation $Mdn = 137 (IR = 64)$ No/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation $56 (91.8\%)$ No56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy $48 (73.8\%)$ ACEI or ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivabradine7 (10.8%)Other pharmacologic therapy $17 (26.2\%)$ Acetylsalicylic acid36 (55.4%)		
Mitral regurgitationNo/Mild51 (84.60%)Moderate/severe10 (15.40%)Tricuspid regurgitation56 (91.8%)No56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy48 (73.8%)ACEI or ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivabradine70.8%)Other pharmacologic therapy71 (26.2%)Warfarin17 (26.2%)Acetylsalicylic acid36 (55.4%)		
No/Mild 51 (84.60%) Moderate/severe 10 (15.40%) Tricuspid regurgitation 10 (15.40%) No 56 (91.8%) Moderate 5 (8.20%) Right ventricular dysfunction 48 (73.8%) Heart failure pharmacologic therapy 48 (73.8%) ACEI or ARA 65 (100%) Beta-adrenergic blockers 60 (92.3%) Aldosterone antagonists 53 (81.5%) Diuretics 46 (70.8%) Nitrates 5 (77%) Digoxin 18 (27.7%) Ivabradine 7 (10.8%) Other pharmacologic therapy 17 (26.2%) Marfarin 17 (26.2%) Acetylsalicylic acid 36 (55.4%)		Mdn = 137 (IR = 64)
Moderate/severe10 (15.40%)Tricuspid regurgitation		
Tricuspid regurgitationNo56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy		
No56 (91.8%)Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy		10 (15.40%)
Moderate5 (8.20%)Right ventricular dysfunction48 (73.8%)Heart failure pharmacologic therapy		56 (91.8%)
Heart failure pharmacologic therapyACEI or ARA65 (100%)Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivabradine7 (10.8%)Other pharmacologic therapy7Warfarin17 (26.2%)Acetylsalicylic acid36 (55.4%)	Moderate	
ACEI or ARA 65 (100%) Beta-adrenergic blockers 60 (92.3%) Aldosterone antagonists 53 (81.5%) Diuretics 46 (70.8%) Nitrates 5 (77%) Digoxin 18 (27.7%) Ivabradine 7 (10.8%) Other pharmacologic therapy 17 (26.2%) Acetylsalicylic acid 36 (55.4%)		48 (73.8%)
Beta-adrenergic blockers60 (92.3%)Aldosterone antagonists53 (81.5%)Diuretics46 (70.8%)Nitrates5 (77%)Digoxin18 (27.7%)Ivabradine7 (10.8%)Other pharmacologic therapy7Warfarin17 (26.2%)Acetylsalicylic acid36 (55.4%)		GE (100%)
Aldosterone antagonists 53 (81.5%) Diuretics 46 (70.8%) Nitrates 5 (77%) Digoxin 18 (27.7%) Ivabradine 7 (10.8%) Other pharmacologic therapy 7 Warfarin 17 (26.2%) Acetylsalicylic acid 36 (55.4%)		
Diuretics 46 (70.8%) Nitrates 5 (77%) Digoxin 18 (27.7%) Ivabradine 7 (10.8%) Other pharmacologic therapy 7 (10.8%) Warfarin 17 (26.2%) Acetylsalicylic acid 36 (55.4%)		
Digoxin 18 (27.7%) Ivabradine 7 (10.8%) Other pharmacologic therapy 7 (26.2%) Warfarin 17 (26.2%) Acetylsalicylic acid 36 (55.4%)		
Ivabradine7 (10.8%)Other pharmacologic therapy7Warfarin17 (26.2%)Acetylsalicylic acid36 (55.4%)		5 (77%)
Other pharmacologic therapy Warfarin17 (26.2%)Acetylsalicylic acid36 (55.4%)		
Warfarin 17 (26.2%) Acetylsalicylic acid 36 (55.4%)		/ (10.8%)
Acetylsalicylic acid 36 (55.4%)		17 (26.2%)

3062

Table 1 (continued)

Characteristic	N (%)	
OADs	20 (30.8%)	
Insulin	12 (18.5%)	
Statin	49 (75.4%)	
Fibrate	2 (3.1%)	
PPI	38 (58.5%)	
Electronic device		
None	27 (41.5%)	
ICD	21 (32.3%)	
CRT	17 (26.2%)	

Questionnaire	Score Mean \pm SD	Category	N (%)
MoCA ^a	17.22 ± .86	MCI	59 (92.2)
HADS-Anxiety ^b	7.53 ± 4.45	Anxiety	19 (29.7)
b		Borderline	10 (15.4)
HADS-Depression ^D	7.03 ± 4.38	Depression	12 (18.5)
<i>.</i>		Borderline	19 (29.2)
PSS-10 ^c	17.77 ± 6.334	Perceived stress	24 (36.9)

ACEI, angiotensin-converting-enzyme inhibitor; ARA, angiotensin II receptor antagonists; BMI, body mass index; CRT, cardiac resynchronization therapy; df, degrees of freedom; DOACs, direct-acting oral anticoagulants; EF, ejection fraction; ICD, implantable cardioverter defibrillator; IR, interquartile range; LVEF, left ventricular ejection fraction; M, mean; MCI, mild cognitive impairment; Mdn, median; NYHA, New York Heart Association; OAD, oral antidiabetic drugs; Pro-BNP, pro-brain-type natriuretic peptide; PPI, proton pump inhibitor; *phi*, phi coefficient; *r*, Pearson's correlation presented as r(df); *rs*, Spearman's rho, presented as rs(df); SD, standard deviation; *P < 0.001

^aMoCA, Montreal Cognitive Assessment, mild cognitive impairment cut-off: <24, 7 points, adjusted to the Portuguese population for all ages and years of school.

^bHADS, Hospital Anxiety and Depression Scale, Anxiety (HADS-A) and Depression (HADS-D) subscales, pathological score if >10 points, borderline score if ranging 8 to 10 points.

^cPSS-10, Perceived Stress Scale, score \geq 20 indicative of high level of perceived stress.

of gender, age, and school years in anxiety, depression, and cognitive performance, these parameters were included in the analysis. We found a significant association between anxiety and depression (r(64) = 0.559; P < 0.001); perceived stress and anxiety (r(64) = 0.357; P < 0.001); and perceived stress and depression (r(64) = 0.252; P = 0.045). There was also a significant correlation between age and school years (r(65) = -0.611; P < 0.001); and between depression and school years (r(64) = 0.229; P = 0.048). MoCA scores were significantly associated with the number of school years (rMoCA(64) = 0.436; P < 0.001) and age (rMoCA(64) = -0.556; P < 0.001). Psychometric scores, such as anxiety, depression, and perceived stress, as well as KCCQ scores, demonstrated no association with cognitive performance.

Major adverse cardiovascular event-free survival and mortality

As shown in *Table* 3, 40% of the patients had at least one MACE during the follow-up period. From all MACE, 14.5% were CV hospitalizations, 69% were CV emergency department visits, and 15.4% were CV-related deaths. The average time for the first MACE event was 255 days. The overall mortality rate of our cohort was 13.8%; in the first year of follow-up, the mortality rate was 7.7%, and in the second year, it was 6.2%.

As previously referred on the Methods section, we used Cox regression models to search for predictors of

Parameter	HADS-Anxiety	HADS-Depression	MoCA	PSS10	Age	Gender
HADS-Depression MoCA PSS-10 Age Gender ^a Years of scholarity	0.559 ^{**} (64) -0.037 (63) ^b 0.357 ^{**} (64) -0.042 (64) ^b -0.148 (64) ^b -0.006 (64) ^b	$\begin{array}{r} -0.178\ (63)^{\rm b}\\ 0.252\ ^{*}\ (64)\\ 0.158\ (64)\\ -0.225\ (64)^{\rm b}\\ -0.229\ ^{*}\ (64)\end{array}$	$\begin{array}{c} 0.0112 \ (63)^{\rm b} \\ -0.556^{**} \ (64) \\ 0.17 \ (64)^{\rm b} \\ 0.436^{**} \ (64) \end{array}$	-0.011 (65) ^b -0.061 (65) ^b 0.12 (64) ^b	-0.114 (65) ^b -0.611* (65)	0.206 (65) ^b

HADS, Hospital Anxiety and Depression Scale; MoCA, Montreal Cognitive Assessment; PSS-10, Perceived Stress Scale. P < 0.05.

^{**}*P* < 0.001.

^aGender, reference category: female.

^bSpearman's rho.

Table 3 Characteristics of the MACE

Characteristic Days to event	Mean (SD)
Days to MACE	255.00 (214.84)
Days to first hospitalization	267.27 (219.76)
Days to first CV hospitalization	289.00 (230.68)
Days to first ED event	193.85 (157.39)
Days to first ED CV event	300.80 (231.36)
Days to death	312.78 (195.24)
Number of events	<i>n</i> (%)/Mean (SD)
MACE	26 (40.0%)/0.40 (0.49)
MACE CV hospitalizations	4 (15.4%)
MACE ED-CV	18 (69.2%)
MACE Death	4 (15.4%)
Hospitalizations	61 (100%)/0.94 (1.39)
Non elective hospitalizations	48 (78.7%)/0.74 (1.33)
CV hospitalizations	32 (52.5%)/0.49 (1.09)
ED	144 (100%)/2.22 (3.05)
ED-CV	42 (29.2%)/0.65 (1.26)
ED-non-CV	102 (70.8%)/1.55 (2.17)
	N (Mortality rate)
Death	9 (13.8%)

CV, cardiovascular; ED, emergency department; SD, standard deviation; MACE, major adverse cardiovascular event.

MACE-free survival. We used a stepwise forward selection method that included the following variables: age, gender, years of school, MoCA, HADAS-A, HADS-D, and KCCQ. On the univariate analysis, MoCA and KCCQ were the only variables significantly associated with MACE-free survival (*Table* 4). These two were combined on a model that was statistically significant for predicting MACE-free survival. In this model, a 1-point increase in MoCA score was associated with a decreased risk of MACE [hazard ratio (HR) = 0.906; 95% confidence interval (CI) = 0.829–0.990; P = 0.029] independently of the KCCQ score. While significant, the association between KCCQ score and MACE-free survival was weak (HR = 0.986; CI = 0.973–0.999; P = 0.031). The model did not survive correction for further addition of other variables. It is important to highlight that

 Table 4
 Cox-regressions for MACE-free survival and the neuropsychological parameters scores

Model	MACE-free survival ^a		
	HR (95% CI)	P value	
Univariable Cox regression model			
MoCA	0.894 (0.819–0.977)	0.012	
KCCQ	0.982 (0.969–0.996)	0.011	
Multivariable Cox regression model			
MoCA	0.906(0.829–0.990)	0.029	
KCCQ	0.986 (0.973-0.999)	0.031	
KCCQ 0.986 (0.973–0.999) 0.031 Final overall model (χ^2 = 12.220; <i>df</i> = 2; <i>P</i> = 0.002)			

CI, confidence interval; HR, hazard ratio; KCCQ, Kansas City Cardiomyopathy Questionnaire; MACE, major adverse cardiovascular event; MoCA, Montreal Cognitive Assessment;.

There was no association between MACE-free survival and age (P = 0.101), gender (P = 0.734, HADS-A (P = 0.665), HADS-D (P = 0.391), and years of school (P = 0.709).

we used MoCA scores as a continuous variable, which makes it independent of the categorization of the clinical entity (mild CI or dementia).

We used a similar approach to search for predictors of mortality. On the univariate analysis, age and KCCQ were the only variables associated with mortality. However, KCCQ lost significance when adjusted for age. As so, age persisted as the main predictor of mortality (HR = 1.091; CI = 1.012-1.177; P = 0.017).

Health-related quality of life evaluation

Health-related quality of life was assessed by the KCCQ. Its overall summary score mean was 64.3 ± 24.7 points; the domains, 'self-efficacy' and 'knowledge', 'symptoms frequency', and 'symptoms burden', showed the higher scores (means of 87.5; 72.9 and 71.5, respectively).

To better understand the strength of the relationship between KCCQ and the other battery test scores, we performed a Pearson's correlation (*Table* 5) that demonstrated a significant correlation between KCCQ levels and anxiety (R(65) = -0.390), depression (R(65) = -0.378), and perceived stress (R(64) = -0.333) levels.

To determine if anxiety, depression, and perceived stress are predictors of HrQoL, we performed a multilinear regression model. As shown in *Table* 5, this model was able to explain 38.8% of the variance of the KCCQ score (F(3.60) = 12.704, P < 0.001). Also, both anxiety ($\beta = -0.326$; P = 0.012) and depression ($\beta = -0.309$; P = 0.014) scores were independently associated with worst HrQoL.

 Table 5
 Inferential analysis to explore the correlation between

 KCCQ score and neuropsychological parameters and MACE-free
 survival

A. Pearson correlation coefficients between neuropsychological parameters and KCCQ score

	KCCQ Pearson coefficient (R); (N)		
MoCA	0.074 (64)		
HADS-A	-0.390 ** (65)		
HADS-D	-0.378 ^{**} _{**} (65)		
PSS-10	-0.333 ^{**} (64)		
Age	-0.049 (65)		
Years of school	0.082 (65)		

B. Multiple linear regression models between HADS-A, HADS-D, PSS-10, and KCCQ score

	KCCQ score		
	B [CI 95%]	SE Beta	
HADS-A	-1.642 [-2.915; 0.369]	- 0.636 -0.326*	
HADS-D	-1.580 [-2.828; 0.331]	- 0.624 -0.309*	
PSS	-0.490 [- 1.255;0.275]	0.502 0.155	
F.R ² and R adjusted	F(3.60) = 12.704	**; 0.388; 0.358	

CI, confidence interval; HADS, Hospital Anxiety and Depression Scale; HR, hazard ratio; KCCQ, Kansas City Cardiomyopathy Questionnaire; MACE, major adverse cardiovascular event; MLRM, Multivariate Linear Regression Model; MoCA, Montreal Cognitive Assessment; PSS-10, Perceived Stress Scale; SE, standard error. P < 0.05.

[™]P < 0.001.

^aAdjusted for age.

The Pearson's correlation demonstrates a significant correlation between KCCQ levels and anxiety (R(65) = -0.390), depression (R(65) = -0.378) and perceived stress (R(64) = -0.333) levels. The MLRM was able to explain 38.8% of the variance of the KCCQ score (F(3.60) = 12.704, P < 0.001). Also, both anxiety ($\beta = -0.326$; P = 0.012) and depression ($\beta = -0.309$; P = 0.014) were independently associated with worst quality of life. On the longitudinal evaluation, KCCQ was a predictor of MACE-free survival when adjusted to age.

Discussion

In this study, we explored the value of neuropsychological assessment tools to predict events and quality of life in patients with HF. Our data show that both lower MoCA and KCCQ scores are predictors of MACE-free survival. These results are in line with other studies showing that lower scores in MoCA and KCCQ are associated with poor health outcomes in adults with HF.²⁷⁻³¹ A possible explanation for this finding is that lower MoCA and KCCQ scores reflect greater severity of HF and consequently worst outcome; another explanation, especially for the predictive value of MoCA, is that mild CI may be associated with poorer self-care and therapeutic compliance, although we did not explore this topic on our study. Recently, the OPERA-HF study⁸ found that psychosocial variables (presence of frailty, moderate-to-severe depression, and moderate-to-severe anxiety) were independently associated with both the first and recurrent adverse events

in patients with HF. In that study, the presence of CI was independently associated only with an increased risk of recurrent events.⁸ However, a direct comparison with our study cannot be performed for several reasons. First, the tool used on OPERA-HF to assess cognitive performance is different from the ones herein used; second, the cohort of OPERA-HF included patients with preserved ejection fraction, and finally, the events accounted for the referred study were not only CV events, unlike the criteria used in our study that was restricted to MACE. Another noteworthy finding of our study was the very high prevalence of CI (92%). This may be explained not only by the severity of HF on our cohort (patients with reduced ejection fraction) but also by the high prevalence of alcohol consumption and low-level of academic education.

The pathophysiology of CI in HF is not completely understood,⁵ but some studies suggest that the reduction in cerebral blood flow, alterations of cerebrovascular reactivity, and modification of baseline levels of blood pressure¹ play an important role. Neuroanatomical changes such as reduced regional cortical thickness,⁵ smaller grey matter volume,³² and reduction of hippocampus volume^{33,34} have been well documented. Of notice, an important finding of the current study was the lack of significant association between MoCA score and clinical parameters (such as NYHA class, Pro-BNP and left ventricular ejection fraction). The same holds for the HrQoL component. The perception of patients of their own HrQoL was not associated with cognitive performance. There are controversial findings in the literature about this topic with some studies reporting a negative impact of CI in guality of life,³⁰ while others show no association.³¹

The present study did not find any significant association between CI and depression, anxiety, or stress, which is contrary to findings from other studies, where a consistent association between depression and cognition has been reported.^{35,36} One possible explanation for this lack of association may be that in patients with HFrEF, cardiac dysfunction is the dominant cause for CI, diluting the effects of other factors such as education or depression. However, a different study design is needed to address this question (p.e. case– control study).

On our cohort, anxiety and depressive symptoms were not associated with CI or MACE but were correlated with the worst quality of life reinforcing the importance of screening and managing anxious and depressive symptoms in patients with HF. The efficacy of pharmacological and non-pharmacological strategies to treat depression is yet to be completely determined in patients with HF.³⁷ Further studies are needed to clarify the best approach to tackle neuropsychological disorders in these patients.

The current study presents limitations. The major limitation is the size of the cohort, although it should be highlighted that this study population represents a subgroup of patients with HFrEF under follow-up in a hospital outpatient setting. While this brings specificity to the current study, it makes it impossible to determine if the results can be extrapolated to other populations of patients, such as those with HF with preserved or mid-range EF or who do not attend follow-up at the hospital. Another limitation was the descriptive nature of the study, which does not allow determining the mechanisms underlying the predictive value of MoCA and KCCQ scores for MACE-free survival time. Finally, external factors in patient selection may have influenced the results, such as the willingness to participate in the study.

In summary, our study concludes that the prevalence of mild CI is very high in patients with HFrEF and, of greater clinical relevance, MoCA, and KCCQ scores predict MACE-free survival. On the contrary, anxiety and depression performed poorly to predict MACE-free survival but were good predictors of quality of life in this cohort. Overall, these results highlight the importance of neuropsychological and HrQoL parameters in the management of patients with HFrEF.

Statistical analysis

A descriptive analysis was conducted. For quantitative variables, the average and standard deviation, (if normal distribution) and the median and IR (if non-normal distribution) were used. For categorical variables, the absolute and relative (%) frequencies are presented. A two-sample *t*-test was used to study the differences between provenience hospital groups and between cohorts, for quantitative variables. To study differences between groups and association between categorical variables, the χ^2 was used, or the Fisher's exact test, when one of χ^2 test assumptions was violated. Pearson's χ^2 test was used whenever possible.

To measure the strength of associations between quantitative variables, the Pearson correlation was used, or Spearman's rho if any assumption was violated.

To determine which variables predicted MACE-free survival time in this sample, we used Cox regression analysis. To determine which variables predicted KCCQ, we performed a univariate analysis followed by a multiple linear regression model.

Statistical differences were considered significant when P value < 0.05. Data were analysed using the software IBM SPSS version 24.0.

Conflict of interest

None declared.

Funding

This work was done within the project (NORTE-01-0124-FEDER-000021), supported by the Portuguese North Regional Operational Program (ON.2 - O Novo Norte), under the National Strategic Reference Framework (QREN), through the European Regional Development Fund (FEDER); by the project (NORTE-01-0145-FEDER-000013), supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER); and by FEDER funds, through the Competitiveness Factors Operational Programme (COMPETE).

References

- Bauer LC, Johnson JK, Pozehl BJ. Cognition in heart failure: an overview of the concepts and their measures. J Am Acad Nurse Pract 2011; 23: 577–585.
- Chapa DW, Akintade B, Son H, Woltz P, Hunt D, Friedmann E, Hartung MK, Thomas SA. Pathophysiological relationships between heart failure and depression and anxiety. *Crit Care Nurse* 2014; 34: 2.
- Vongmany F, Hickman LD, Lewis J, Newton PJ, Phillips JL. Anxiety in chronic heart failure and the risk of increased hospitalizations and mortality: a systematic review. *Eur J Cardiovasc Nurs* 2016; 15: 478–485.
- Wei J, Rooks C, Ramadan R, Shah AJ, Bremner JD, Quyyumi AA, Kutner M, Vaccarino V. Meta-analysis of mental stress—induced myocardial ischemia

and subsequent cardiac events in patients with coronary artery disease. *Am J Cardiol* 2014; **114**: 187–192.

- Leto L, Feola M. Cognitive impairment in heart failure patients. J Geriatr Cardiol 2014; 11: 316–328.
- Jiang W, Kuchibhatla M, Cuffe MS, Christopher EJ, Alexander JD, Clary GL, Blazing MA, Gaulden LH, Califf RM, Krishnan RR, O'Connor CM. Prognostic value of anxiety and depression in patients with chronic heart failure. *Circulation* 2004; 110: 3452–3456.
- Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48: 1527–1537.
- Sokoreli I, Pauws SC, Steyerberg EW, de Vries GJ, Riistama JM, Tesanovic A, Kazmi S, Pellicori P, Cleland JG, Clark AL. Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study. *Eur J Heart Fail* 2018; 20: 689–696.
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2016; **37**: 2129–2200.

- Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in heart failure: a systematic review of the literature. *Eur J Heart Fail* 2007; 9: 440–449.
- Alagiakrishnan K, Mah D, Ahmed A, Ezekowitz J. Cognitive decline in heart failure. *Heart Fail Rev* 2016; 21: 661–673.
- Currie K, Rideout A, Lindsay G, Harkness K. The association between mild cognitive impairment and self-care in adults with chronic heart failure. J Cardiovasc Nurs 2015; 30: 382–393.
- Hawkins MA, Gathright EC, Gunstad J, Dolansky MA, Redle JD, Josephson R, Moore SM, Hughes JW. The MoCA and MMSE as screeners for cognitive impairment in a heart failure population: a study with comprehensive neuropsychological testing. *Heart Lung* 2014; 43: 462–468.
- 14. Cameron J, Worrall-Carter L, Page K, Stewart S, Ski CF. Screening for mild cognitive impairment in patients with heart failure: Montreal cognitive assessment versus mini mental state exam. *Eur J Cardiovasc Nurs* 2013; 12: 252–260.
- Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. JAGS 2015; 53: 695–69920.
- Freitas S, Simões MR, Martins C, Vilar M, Santana I. Estudos de adaptação do Montreal Cognitive Assessment (MoCA) para a população portuguesa. Avaliação Psicológica 2010; 9: 345–357.
- Green PC, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35: 1245–1255.
- Nave-Leal E, Pais-Ribeiro J. Estudo de validação da versão portuguesa do Kansas City Cardiomyopathy Questionnaire. Actas do 7° congresso nacional de psicologia da saúde 2008; 191–194.
- Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983; 24: 385–396.
- Trigo M, Canudo N, Branco F, Silva D. Estudo das propriedades psicométricas da Perceived Stress Scale (PSS) na

população portuguesa. *Psychologica* 2010; **53**: 353–378.

- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 77: 361–370.
- Pais-Ribeiro J, Silva I, Ferreira T, Martins A, Meneses R, Baltar M. Validation study of a Portuguese version of the Hospital Anxiety and Depression Scale. *Psychol Health Med* 2007; 12: 225–237.
- Freitas S, Simões MR, Alves L, Santana I. Montreal Cognitive Assessment (MoCA): normative study for the Portuguese population. J Clin Exp Neuropsychol 2011; 33: 989–996.
- 24. Convenção para a Protecção dos Direitos do Homem e da Dignidade do Ser Humano Face às Aplicações da Biologia e da Medicina: Convenção sobre os Direitos do Homem e da Biomedicina (Conselho da Europa 1997). Resolução da Assembleia da República n.º 1/2001, Diário da República – I Série A, nº 2, 3 de Janeiro de 2001. https://www.coe.int/ en/web/conventions/full-list/-/conventions/rms/090000168007cf98 accessed 01 July 2020.
- Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, Switzerland: CIOMS; 2013.
- European Medicines Agency, Good clinical practice. 2000; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/ WC500004343.pdf accessed 20 January 2020.
- Pereira VH, Costa PS, Santos NC, Cunha PG, Correia-Neves M, Palha JA, Sousa N. Adult body height is a good predictor of different dimensions of cognitive function in aged individuals: a cross-sectional study. Front Aging Neurosci 2016; 8: 217.
- Huynh QL, Negishi K, Blizzard L, Saito M, De Pasquale CG, Hare JL, Leung D, Stantone T, Sanderson K, Venna AJ, Marwick TH. Mild cognitive impairment predicts death and readmission within 30 days of discharge for heart failure. *Int J Cardiol* 2016; **221**: 212–217.
- 29. Gathright EC, Fulcher MJ, Dolansky MA, Gunstad J, Redle JD, Josephson R, Moore SM, Hughes JW. Cognitive function does not impact self-reported health-related quality of life in heart

failure patients. *J Cardiovasc Nurs* 2016; **31**: 405–411.

- Pressler SJ, Subramanian U, Kareken D, Perkins SM, Gradus-Pizlo I, Sauvé MJ, Ding Y, Kim J, Sloan R, Jaynes H, Shaw RM. Cognitive deficits and health-related quality of life in chronic heart failure. J Cardiovasc Nurs 2015; 25: 189–198.
- Gallagher R, Sullivan A, Burke R, Hales S, Sharpe P, Tofler G. Quality of life, social support and cognitive impairment in heart failure patients without diagnosed dementia. *Int J Nurs Pract* 2016; 22: 179–188.
- 32. Alosco ML, Brickman AM, Spitznagel MB, Narkhede A, Griffith EY, Cohen R, Sweet LH, Josephson R, Hughes J, Gunstad J. Reduced gray matter volume is associated with poorer instrumental activities of daily living performance in heart failure. J Cardiovasc Nurs 2016; 31: 31–41.
- 33. Woo MA, Ogren JA, Abouzeid CM, Macey PM, Sairafian KG, Saharan PS, Thompson PM, Fonarow GC, Hamilton MA, Harper RM, Kumar R. Regional hippocampal damage in heart failure. *Eur J Heart Fail* 2015; **17**: 494–500.
- 34. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Miyata S, Furukawa K, Arai H, Fukumoto Y, Taki Y, Shimokawa H. Hippocampal blood flow abnormality associated with depressive symptoms and cognitive impairment in patients with chronic heart failure. *Circ J* 2016; **80**: 1773–1780.
- 35. Garcia S, Spitznagel MB, Cohen R, Raz N, Sweet L, Colbert L, Josephson R, Hughes J, Rosneck J, Gunstad J. Depression is associated with cognitive dysfunction in older adults with heart failure. *Cardiovasc Psychiatry Neurol* 2011; 2011: 368324.
- Sohani ZN, Samaan Z. Does depression impact cognitive impairment in patients with heart failure? *Cardiol Res Pract* 2012; 2012: 524325.
- 37. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010; 56: 692–699.